Champions Oncology Q4 adjusted EBITDA swings to profit of $158,000; revenue rises 12% to $13.8 million
CSBR•Q4 revenue rises as adjusted EBITDA turns positive
- Champions Oncology posted Q4 revenue of $13.8 million, up 12% from a year earlier, as GAAP net loss narrowed to $667,000.
- GAAP operating loss tightened to $522,000; non-GAAP adjusted EBITDA swung to income of $158,000.
- Oncology services margin widened 10 percentage points to 51%, on lower outsourced research services costs and continued radiopharmaceutical work brought in-house.
- For fiscal 2026, revenue rose 4% to $59.4 million, while GAAP net results turned to a $1.18 million loss.
- Management cited continued investment in radiopharmaceuticals, the data platform, and commercial expansion, with adjusted EBITDA positive in all four quarters.
